RMA.Trh4 Db KO cells
Invented by Thorbald Van Hall
Invented at Leiden University and Leiden University Medical Center , Stichting Oncode Institute
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 157677 |
| Antigen/Gene or Protein Targets | Trh4 Db KO |
| Parental Line | RMA |
| Host | Mouse |
| Tissue | Lymphatic Tissue |
| Disease Keywords | Mouse Leukemia |
| Model | Knock-Out |
| Relevance | This cell line overexpresses the ER-resident ceramide synthase Trh4 (transduced by CRISPR) and lacks the H2-Db gene. It serves as a control in helping to understanding T-cell recognition of the Trh4-derived peptide presented by the MHC class I molecule H2-Db. This peptide-epitope is a prototypic example of a neo‐antigen selectively presented by cells with processing defects in the classical MHC class I (MHC‐I) pathway. RMA cells have an intact processing pathway and a functional TAP peptide transporter, but overexpress the Trh4 protein and therefore could present the Trh4 peptide. However, no T cell recognition can be observed due to the absence of the MHC class I H2-Db.This population acts as a clear control. |
| Production Details | Retroviral transduction of the mouse Trh4 gene in an IRES-GFP construct and CRISPR/Cas9 technology |
| Research Area | Cancer |
| Recommended Growing Conditions | Suspension cells in DMEM+8% FCS |
| Positive Control | RMA.Trh4 Kb KO cells |
| Notes |
CRISPR edited RMA cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license. |
| Cellosaurus ID | CVCL_J385 |
References: 1 entry
References: 1 entry
Inventor Information
Inventors
|
Thorbald Van Hall |
